USPTO Patents Application 09589288

Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the
application.

Listing of Claims

1-84. (Cancelled)

85. (Previously Presented) A method of treating an autoimmune system disease or
disorder comprising administering to an individual, an effective amount of an antagonistic
antibody or portion thereof that specifically binds a protein consisting of an amino acid sequence
of amino acid residues 134-285 of SEQ ID NO:2.

86. (Previously Presented) The method of claim 85 wherein the antibody or portion
thereof is a monoclonal antibody.

87. (Previously Presented) The method of claim 85 wherein the antibody or portion
thereof is a polyclonal antibody.

88. (Previously Presented) The method of claim 85 wherein the antibody or portion
thereof is a Fab fragment.

89. (Previously Presented) The method of claim 85 wherein the antibody or portion
thereof is labeled.

90. (Previously Presented) The method of claim 89 wherein the label is selected
from the group consisting of:

(b) a radioisotope;

(c) a fluorescent label; and

(d) biotin.

91 . (Previously Presented) The method of claim 90 wherein the label is a
radioisotope selected from the group consisting of:

(a)

an enzyme label;

(a)

125

I;

(b)

121

i;

Application No.: 09/589,288

Page 4 of 20

Docket No.: PF343P3C5

(c) ,3I I;

(d) 112 In;and

(e) 99m Tc.
92-117. (Cancelled)

118. (Previously Presented) A method of treating rheumatoid arthritis comprising
administering to an individual, an effective amount of an antagonistic antibody or portion
thereof that specifically binds a protein consisting of the amino acid sequence of amino acid
residues 134-285 of SEQ ID NO:2.

119. (Previously Presented) The method of claim 118 wherein the antibody or portion

thereof is a monoclonal antibody.

120. (Previously Presented) The method of claim 118 wherein the antibody or portion
thereof is a polyclonal antibody.

121. (Previously Presented) The method of claim 1 1 8 wherein the antibody or portion
thereof is a Fab fragment.

122. (Previously Presented) The method of claim 1 1 8 wherein the antibody or portion
thereof is labeled.

123. (Previously Presented) The method of claim 122 wherein the label is selected
from the group consisting of:

(a) an enzyme label;

(b) a radioisotope;

(c) a fluorescent label; and

(d) biotin.

124. (Previously Presented) The method of claim 123 wherein the label is a
radioisotope selected from the group consisting of:

(a) ,25 l;

(b) 121 I;

(c) ,3, i;

Application No.: 09/589,288

Page 5 of 20

Docket No.: PF343P3C5

(d)
(e)

112

In; and

99m

Tc.

125-147. (Cancelled)

148. (Previously Presented) A method of inhibiting B lymphocyte proliferation,
differentiation or survival comprising administering to an individual or a cell culture containing
B lymphocytes, an effective amount of an antagonistic antibody or portion thereof that
specifically binds a protein consisting of an amino acid sequence selected from the group
consisting of:

(a) the amino acid sequence of amino acid residues n to 285 of SEQ ID
NO:2, where n is an integer in the range of 2-190;

(b) the amino acid sequence of amino acid residues 1 to m of SEQ ID NO:2,
where m is an integer in the range of 274 to 284; and

(c) the amino acid sequence of amino acid residues n to m of SEQ ID NO: 2,
where n is an integer in the range of 2-190 and m is an integer in the range of 274-284.

149. (Previously Presented) The method of claim 148 wherein the protein consists of
amino acid sequence (a).

150. (Previously Presented) The method of claim 148 wherein the protein consists of
amino acid sequence (b).

151. (Previously Presented) The method of claim 148 wherein the protein consists of
amino acid sequence (c).

1 52. (Previously Presented) The method of claim 1 48 wherein the antibody or portion
thereof is a monoclonal antibody.

153. (Previously Presented) The method of claim 148 wherein the antibody or portion
thereof is a polyclonal antibody.

1 54. (Previously Presented) The method of claim 148 wherein the antibody or portion
thereof is a Fab fragment.

Application No.: 09/589,288 Page 6 of 20 Docket No.: PF343P3C5

155. (Previously Presented) The method of claim 1 48 wherein the antibody or portion
thereof is labeled.

156. (Previously Presented) The method of claim 155 wherein the label is selected
from the group consisting of:

(a) an enzyme label;

(b) a radioisotope;

(c) a fluorescent label; and

(d) biotin.

157. (Previously Presented) The method of claim 156 wherein the label is a
radioisotope selected from the group consisting of:

(a) 125 i;

(b) 121 i;

(c) 131 i;

(d) 112 In;and

(e) 99m Tc.

158. (Previously Presented) A method of inhibiting B lymphocyte proliferation,
differentiation, or survival comprising administering to an individual or a cell culture containing
B lymphocytes, an effective amount of an antagonistic antibody or portion thereof that
specifically binds a protein consisting of an amino acid sequence of amino acid residues 134-285
ofSEQIDNO:2.

1 59. (Previously Presented) The method of claim 158 wherein the antibody or portion
thereof is a monoclonal antibody.

1 60. (Previously Presented) The method of claim 158 wherein the antibody or portion
thereof is a polyclonal antibody.

161 . (Previously Presented) The method of claim 158 wherein the antibody or portion
thereof is a Fab fragment.

1 62 . (Previously Presented) The method of claim 158 wherein the antibody or portion
thereof is labeled.

Application No.: 09/589,288

Page 7 of 20

Docket No.: PF343P3C5

163. (Previously Presented) The method of claim 162 wherein the label is selected
from the group consisting of:

(a) an enzyme label;

(b) a radioisotope;

(c) a fluorescent label; and

(d) biotin.

(Previously Presented) The method of claim 163 wherein the label is a
selected from the group consisting of:

(a) 125 i;

(b) 121 i;

(c) 13l l;

(d) 112 In;and

(e) 99m Tc.

165. (Previously Presented) The method of claim 85 wherein the autoimmune disease
or disorder is systemic lupus erythematosus.

166. (Previously Presented) A method of treating an autoimmune disease or disorder
comprising administering to an individual, an effective amount of an antagonistic antibody or
portion thereof that specifically binds to an isolated recombinant Neutrokine-a protein purified
from a cell culture wherein the cells in said cell culture comprise a polynucleotide encoding
amino acids 1-285 of SEQ ID NO:2 operably associated with a regulatory sequence that controls
gene expression.

167. (Previously Presented) The method of claim 166 wherein the antibody or portion
thereof is a monoclonal antibody.

168. (Previously Presented) The method of claim 166 wherein the antibody or portion
thereof is a polyclonal antibody.

1 69. (Previously Presented) The method of claim 1 66 wherein the antibody or portion
thereof is a Fab fragment.

164.

radioisotope

Application No.: 09/589,288

Page 8 of 20

Docket No.: PF343P3C5

1 70. (Previously Presented)
thereof is labeled.

The method of claim 166 wherein the antibody or portion

171. (Previously Presented) The method of claim 1 70 wherein the label is selected
from the group consisting of:

(a) an enzyme label;

(b) a radioisotope;

(c) a fluorescent label; and

(d) biotin.

172. (Previously Presented) The method of claim 171 wherein the label is a
radioisotope selected from the group consisting of:

(a) 125 i;

(b) 12l i;

(c) 131 i;

(d) 112 In;and

(e) 99m Tc.

173. (Previously Presented) The method of claim 166 wherein the autoimmune
disease or disorder is systemic lupus erythematosus.

1 74. (Previously Presented) A method of treating rheumatoid arthritis comprising
administering to an individual, an effective amount of an antagonistic antibody or portion
thereof that specifically binds to an isolated recombinant Neutrokine-oc protein purified from a
cell culture wherein the cells in said cell culture comprise a polynucleotide encoding amino acids
1-285 of SEQ ID NO:2 operably associated with a regulatory sequence that controls gene
expression.

1 75 . (Previously Presented) The method of claim 1 74 wherein the antibody or portion
thereof is a monoclonal antibody.

1 76. (Previously Presented) The method of claim 1 74 wherein the antibody or portion
thereof is a polyclonal antibody.

Application No.: 09/589,288

Page 9 of 20

Docket No.: PF343P3C5

1 77. (Previously Presented) The method of claim 1 74 wherein the antibody or portion
thereof is a Fab fragment.

1 78. (Previously Presented) The method of claim 1 74 wherein the antibody or portion
thereof is labeled.

179. (Previously Presented) The method of claim 178 wherein the label is selected
from the group consisting of:

(a) an enzyme label;

(b) a radioisotope;

(c) a fluorescent label; and

(d) biotin.

(Previously Presented) The method of claim 179 wherein the label is a
selected from the group consisting of:

(a) 125 i;

(b) 121 i;

(c) 13, l;

(d) 112 In;and

(e) 99m Tc.

181-182. (Cancelled)

183. (Previously Presented) The method of claim 148 which comprises
administering to an individual an effective amount of said antagonistic antibody or portion
thereof.

184. (Previously Presented) The method of claim 148 which comprises
administering to a cell culture containing B lymphocytes an effective amount of said antagonistic
antibody or portion thereof.

185. (Previously Presented) The method of claim 158 which comprises
administering to an individual an effective amount of said antagonistic antibody or portion
thereof.

180.

radioisotope

Application No.: 09/589,288

Page 10 of 20

Docket No.: PF343P3C5

1 86. (Previously Presented) The method of claim 158 which comprises
administering to a cell culture containing B lymphocytes an effective amount of said antagonistic
antibody or portion thereof.

187. (New) The method of claim 85 wherein said antibody or portion thereof is
administered intravenously.

188. (New) The method of claim 85 which comprises administering between 0.1 and
20 mg/kg of the patient's body weight of said antibody or portion thereof.

1 89. (New) The method of claim 118 wherein said antibody or portion thereof is
administered intravenously.

190. (New) The method of claim 118 which comprises administering between 0. 1 and
20 mg/kg of the patient's body weight of said antibody or portion thereof

191. (New) The method of claim 166 wherein said antibody or portion thereof is
administered intravenously.

192. (New) The method of claim 166 which comprises administering between 0.1 and
20 mg/kg of the patient's body weight of said antibody or portion thereof.

193. (New) The method of claim 174 wherein said antibody or portion thereof is
administered intravenously.

194. (New) The method of claim 174 which comprises administering between 0.1 and
20 mg/kg of the patient's body weight of said antibody or portion thereof.

Application No.: 09/589,288

Page 11 of 20

Docket No.: PF343P3C5